Ignite Creation Date:
2025-12-24 @ 2:54 PM
Ignite Modification Date:
2026-02-03 @ 5:17 PM
Study NCT ID:
NCT02470559
Status:
WITHDRAWN
Last Update Posted:
2016-02-17
First Post:
2015-06-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Sponsor:
Barbara Ann Karmanos Cancer Institute
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Malignant Ovarian Clear Cell Tumor | View |
| None | Malignant Ovarian Serous Tumor | View |
| None | Recurrent Fallopian Tube Carcinoma | View |
| None | Recurrent Ovarian Carcinoma | View |
| None | Recurrent Primary Peritoneal Carcinoma | View |
| None | Stage IIIA Fallopian Tube Cancer | View |
| None | Stage IIIA Ovarian Cancer | View |
| None | Stage IIIA Primary Peritoneal Cancer | View |
| None | Stage IIIB Fallopian Tube Cancer | View |
| None | Stage IIIB Ovarian Cancer | View |
| None | Stage IIIB Primary Peritoneal Cancer | View |
| None | Stage IIIC Fallopian Tube Cancer | View |
| None | Stage IIIC Ovarian Cancer | View |
| None | Stage IIIC Primary Peritoneal Cancer | View |
| None | Stage IV Fallopian Tube Cancer | View |
| None | Stage IV Ovarian Cancer | View |
| None | Stage IV Primary Peritoneal Cancer | View |
Keywords: